Retatrutide Medicine

Citations

Primary sources and full reference list

Every citation used on this site, with DOIs and PubMed or PMC URLs.

Retatrutide references

All citations are numbered to match inline [N] references used across the site. Each entry includes the DOI and a direct link to the primary source.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. PMC11255275. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. PMC11271400. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. PMC12190491. ↗
  7. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. ↗
  8. et al. Dietary protein defends lean mass and maintains the metabolic benefits of weight loss. Mol Metab. 2024. PMC11424806. ↗
  9. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. 2024;2(1):31. PMC12118674. ↗
  10. Derawi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. PMC11536522. ↗
  11. Kusminski CM, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell. 2024;187(15):3829-3853. PMC11286204. ↗
  12. Hitaka K, et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. International Journal of Obesity. 2026. ↗
  13. Li Q, et al. Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Diabetology & Metabolic Syndrome. 2026. ↗